Shots:
- The approval is based on P-III ATLAS, FLAIR and ATLAS-2M studies assessing Vocabria (cabotegravir) + Janssen’s Rekambys (rilpivirine inj.) or Edurant (rilpivirine tablets) in 1200+ patients for HIV-1 infection in adults who are virologically suppressed
- The first long-acting injectable can enable people living with HIV to reduce the days they receive treatment from 365 to 12 or 6/year. Most of the clinical trial patients who tried the treatment over their previous daily oral therapy preferred the new treatment
- The approval marks the second approval of the long-acting regimen of cabotegravir and rilpivirine, with once-monthly dosing licensed by Health Canada under the brand name Cabenuva
Click here to read full press release/ article | Ref: Businesswire | Image: The Pharma Letter
The post ViiV Healthcare’s First Long-Acting Injectable Receive EC’s Approval for the Treatment of HIV first appeared on PharmaShots.
